Award winning Director is going to direct three renowned stars of Hollywood. These frames do not need any introduction. This is a very rare combination and definitely be a block buster.
Want a sneak peek of the latest cell phone technology or newest flat screen TV? Are you anticipating the release of the newest appliances that will soon be featured in your kitchen?
The International Consumer Electronics Show (CES) is back! CES is the world’s gathering place for all who thrive on the business of consumer technologies. Held in Las Vegas every year, it has served as the proving ground for innovators and breakthrough technologies for more than 40 years—the global stage where next-generation innovations are introduced to the marketplace.
It’s not only the world's largest annual tradeshow for consumer technology, but it is also America's largest annual tradeshow of any kind. The first CES took place in New York City in June of 1967 with 200 exhibitors and 17,500 attendees. Since then, CES has grown more than seven-fold. CES now showcases more than 3,600 exhibiting companies, including manufacturers, developers and suppliers of consumer technology hardware, content, technology delivery systems and more and more than 150K attendees from 150 countries.
Nationally recognized consumer trends and technology expert Todd Townsend will provide viewers with a rare preview of some the latest technology available for 2016.
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex® (cannabidiol) in children with Dravet syndrome.1 Epidiolex, GW’s lead product candidate and the potential first in a new category of anti-epileptic drugs, is a liquid formulation of purified, plant-derived cannabidiol (CBD), a non-psychoactive cannabinoid, which is being studied for the treatment of a number of rare, severe pediatric-onset epilepsy disorders. In the study, Epidiolex significantly reduced monthly convulsive seizure frequency compared to placebo in highly treatment-resistant children when added to existing treatment. Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior open label experience.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8109951-gw-pharmaceuticals-study-epidiolex/
Boehringer Ingelheim announced today a new partnership with Minor League Baseball® (MiLB™) to further raise awareness of the rare lung disease idiopathic pulmonary fibrosis (IPF) through its Breathless™ campaign. Now the “Official IPF Awareness Partner of Minor League Baseball,” Boehringer Ingelheim will work with the league to educate its fan base about symptoms of IPF – and the importance of an early diagnosis and treatment – through in-stadium events as well as appearances by New York Yankees legend and musician Bernie Williams, whose father passed away from the disease in 2001.
To view the multimedia release go to:
https://www.multivu.com/players/English/8289951-boehringer-ingelheim-milb-partnership-for-ipf-awareness/
1946 ultra rare $100,000 error cent. Improper alloy mix video and rare off metal strikes. These type of Errors are Extreemly Rare especially when they are old like this one... 1946 wheat cent. Major sites are showcasing 4 and auctions sites are hardly showing any for sale. A $100,000.00 dollar value. A collectores dream come True. I love Treasure Hunting for Rare Lincoln Cents.. God Bless America!!!
New York Yankees all-time great Bernie Williams is teaming up with Boehringer Ingelheim to raise awareness of a lung disease called idiopathic pulmonary fibrosis (IPF) that his father suffered from for years before he passed away in 2001. His father, Bernabé, inspired Williams to play baseball and make it to the Major Leagues, and taught him to play guitar which has become William’s second career since retiring from baseball.
In honor of his father’s battle with IPF, Williams has joined the Breathless™ campaign to turn his family’s devastating experience with this rare lung disease into a chance to help other families. Williams hopes to educate and empower others who think they may have IPF to seek early diagnosis and treatment and is encouraging people to visit the campaign website – www.BreathlessIPF.com – and share the videos and educational content through social media channels such as Facebook and Twitter.
To view the multimedia release go to:
https://www.multivu.com/players/English/8058551-bernie-williams-ipf-breathless-campaign/
Today on Rare Disease Day, My Life, Our Future, a national program founded by leaders in the bleeding disorder community, including Bloodworks Northwest, the American Thrombosis and Hemostasis Network, the National Hemophilia Foundation and Bioverativ Inc., opened the largest research repository of its kind in the world to scientists. The My Life, Our Future Research Repository is a collection of genetic data and blood samples that are linked to phenotypic data from more than 5,000 people in the U.S. with hemophilia, a rare disorder that impairs the ability of one’s blood to clot. The My Life, Our Future Research Repository will allow researchers to advance the scientific understanding of the disorder, including genetic differences that affect bleeding severity and reaction to certain treatments.
To view the multimedia release go to:
https://www.multivu.com/players/English/8046151-national-hemophilia-foundation-my-life-our-future/
